GovWire

Decision: Regulatory approval of adapted Spikevax (formerly COVID-19 Vaccine Moderna) XBB.1.5 vaccine

Medicines Healthcare Products Regulatory Agency

April 17
09:05 2024

Summary of Product Characteristics - Moderna (Spikevax) XBB.1.5 vaccine

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email webupdates@mhra.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Patient Information Leaflet - Moderna (Spikevax) XBB.1.5 vaccine

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email webupdates@mhra.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

The 15-minute observation period following vaccination with the mRNA COVID-19 vaccines has been removed for individuals aged 12 years and over who have no history of a severe allergic reaction (as outlined in the Greenbook advice. This follows careful review of the safety data by the MHRA and advice from the governments independent Commission on Human Medicines. A temporary suspension of the 15-minute observation period for children aged 5-11 years remains in place and this will be reviewed on a regular basis. A temporary suspension will also apply for infants and children aged 6 months to 5 years, should this age group be included in the vaccination programme.

The product information for the following Spikevax vaccines can be found on the pages below:

The Summary of Product Characteristics is a description of a medicinal products properties and the conditions attached to its use. It explains how to use and prescribe a medicine. It is used by healthcare professionals, such as doctors, nurses and pharmacists.

The Patient Information Leaflet provides information for patients on using the medicine safely. This is based on the Summary of Product Characteristics of the product.

The Public Assessment Report (PAR) is a scientific report, written by the?MHRA and will be published shortly. It explains how this product was assessed and how its authorisation was recommended, as well as its conditions of use. It is not intended to provide practical advice on how to use this product.

This new marketing authorisation granted by the MHRA is valid in Great Britain only and was approved via the national licensing route.

See further information in our news story.

Ingredients

The?MHRA?can confirm that Spikevax does not contain any components of animal origin.

A full list of ingredients for the qualitative and quantitative composition of the vaccine can be found at point 2 in the Summary of Product Characteristics.

A full list of ingredients for the excipient composition of the vaccine can be found at point 6.1 in the Summary of Product Characteristics.

A full list of ingredients for the qualitative and quantitative composition of the vaccine and a full list of the excipient composition of the vaccine can be found at point 6 in the Patient Information Leaflet.

Published 15 September 2023
Last updated 17 April 2024 +show all updates
  1. Update the SmPC and PIL to include chronic urticar

Related Articles

Comments

  1. We don't have any comments for this article yet. Why not join in and start a discussion.

Write a Comment

Your name:
Your email:
Comments:

Post my comment

Recent Comments

Follow Us on Twitter

Share This


Enjoyed this? Why not share it with others if you've found it useful by using one of the tools below: